How WEHI Scientists Are Helping Defeat Malaria: From Fundamental Discovery to New Treatments
How WEHI Scientists Are Helping Defeat Malaria: From Fundamental Discovery to New Treatments
Why Malaria Still Matters
Malaria has been one of humanity's deadliest infectious diseases for thousands of years. Although remarkable progress has been been made over the past two decades, the disease still causes hundreds of thousands of deaths every year, with young children in sub-Saharan Africa carrying the greatest burden.
Drug-resistant parasites, insecticide-resistant mosquitoes, and the parasite's remarkably complex life cycle continue to challenge scientists around the world.
For decades, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne have contributed to this global effort by asking one fundamental question: How does the malaria parasite survive inside the human body?
Understanding the Malaria Parasite
Malaria is caused by Plasmodium parasites, which are transmitted through the bite of infected Anopheles mosquitoes.
After entering the body, the parasites first infect liver cells before moving into red blood cells, where they multiply rapidly and trigger the fever, anaemia, and life-threatening complications associated with malaria.
Because this blood stage causes most of the disease, understanding how parasites invade and survive inside red blood cells has become one of the major goals of malaria research.
WEHI's Contribution to Malaria Research
For more than three decades, WEHI scientists have combined molecular biology, structural biology, genetics, and immunology to understand malaria at the cellular level.
Rather than focusing only on developing drugs, researchers have sought to answer basic biological questions about how the parasite enters red blood cells, remodels its host cell, escapes immune detection, and reproduces.
These discoveries have identified potential weak points that may become targets for future medicines and vaccines.
From Laboratory Discovery to the novel antimalarial candidate MK-7602
Many successful medicines begin with a simple biological discovery rather than an obvious drug target.
The same philosophy has guided WEHI's malaria program. By uncovering the molecular mechanisms that parasites use to invade red blood cells and survive within them, researchers have revealed entirely new opportunities for drug development.
Other studies have improved our understanding of naturally acquired immunity, helping scientists identify parasite proteins that may serve as future vaccine candidates.
Although these discoveries often take many years to translate into medicines, they provide the scientific foundation on which future therapies are built.
One remarkable outcome of this long journey is MK-7602, a first-in-class antimalarial drug candidate developed through collaboration between WEHI and MSD. After years of laboratory research, it has now entered human clinical trials. In our next article, we'll explore how MK-7602 performed in its first Phase 1 study and why researchers are excited about its future.
Looking to the Future
The fight against malaria is far from over. As parasites continue to evolve resistance to existing medicines, scientists must continually discover new drug targets and new therapeutic strategies.
Modern technologies such as genome sequencing, cryo-electron microscopy, single-cell analysis, and artificial intelligence are accelerating this process by revealing parasite biology in unprecedented detail.
WEHI continues to contribute to these international efforts, working with collaborators around the world to better understand one of humanity's oldest infectious diseases.
Conclusion
Every breakthrough against malaria begins with curiosity-driven science. Long before a medicine reaches patients, researchers must first understand how the parasite infects, survives, and causes disease.
WEHI's malaria research demonstrates how fundamental discoveries made in the laboratory can eventually contribute to the development of better drugs, improved vaccines, and new strategies for controlling one of the world's most devastating infectious diseases.